Innovent Biologics, Inc. (OTCMKTS:IVBXF) Stock Short Interest Report for October

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a large increase in short interest in October. As of October 30th, there was short interest totaling 30,939 shares, an increase of 138.0% from the October 15th total of 13,000 shares. Based on an average daily volume of 5,135 shares, the short-interest ratio is currently 6.0 days.

Innovent Biologics Stock Down 0.0%

IVBXF stock traded down $0.00 during mid-day trading on Friday, reaching $11.08. The company had a trading volume of 831 shares, compared to its average volume of 3,616. The stock has a 50 day simple moving average of $11.88 and a two-hundred day simple moving average of $11.23. Innovent Biologics has a 52 week low of $9.10 and a 52 week high of $15.01.

About Innovent Biologics

Innovent Biologics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. The company primarily targets oncology, autoimmune, cardiovascular and metabolic diseases, with an emphasis on biologic therapies, biosimilars and other specialty treatments. Its marketed and development portfolio includes therapies such as TYVYT (sintilimab), a PD-1 inhibitor developed in collaboration with Eli Lilly, as well as products based on or related to bevacizumab, rituximab and adalimumab.